Nestlé & Novo Nordisk: This Week's Top Healthcare Stories
Nestlé has initiated a voluntary recall of certain batches of its SMA Infant Formula and Follow-On Formula in the UK and Ireland due to a potential presence of the toxin cereulide. The company is offering full refunds for returned products.
“There have been no confirmed reports of any illness associated with consumption of the products concerned,” Nestlé states.
“Nevertheless, out of an abundance of caution, Nestlé has decided to perform this voluntary product recall in line with our strict product quality and safety protocols.”
For global pharmaceutical company Novo Nordisk, 2026 holds a lot of potential.
As it works on bouncing back from last year’s setbacks, it aims to grow its presence in the US weight loss market.
Novo Nordisk’s CEO, Mike Doustdar, reflected on the year on LinkedIn and shared the company’s plans for the future, including improving its performance and building trust with patients, partners and investors.
Cera, the home healthcare innovator, is developing a suite of AI care agents.
The agents are designed to automate time-consuming tasks, make decisions based on information they gather and act on them by using reasoning, planning and memory.
Cera is set to introduce almost 1,000 agents across its 10,000-strong workforce, speeding up recruitment of carers, organising replacement cover and continuously reviewing and improving patient care quality and compliance.
Novartis, one of the world’s largest pharmaceutical companies, has sharpened its sustainability focus under the leadership of Korab Zuka, who took the role of Global Head of Social Impact and Chief Sustainability Officer at the end of 2024.
Korab, who joined Novartis a year ago, brings a career shaped by social impact work in both the public and private sectors. His role unites sustainability, access to medicine and the company’s philanthropic foundations under one strategy.
For Korab, sustainability is about more than environmental targets. It is intrinsically tied to human health and to Novartis’ mission of widening access to its scientific breakthroughs. As he puts it: “In order for people to have healthy lives, you have to have a healthy planet.”
Japan's ageing population crisis has inspired an ambitious partnership between Fujitsu and Nvidia, aimed at revolutionising healthcare delivery through artificial intelligence.
The collaboration centres on developing a healthcare orchestrator platform that coordinates multiple AI agents to streamline administrative tasks, allowing medical professionals to focus on patient care.
With Japan having the world's highest percentage of people over 65, the healthcare system faces mounting pressure on resources and staff.
Fujitsu, generating approximately US$24.64bn in revenue last fiscal year with a global workforce of 113,000, has identified healthcare AI as a critical growth sector within its broader strategy to address societal challenges.
Executives
Dr. Ben Maruthappu
Founder & CEO
Jensen Huang
Founder and CEO
Korab Zuka
Global Head of Social Impact and Chief Sustainability Officer
Maziar Mike Doustdar
President and CEO
Philipp Navratil
Chief Executive Officer
